Adam Feuerstein and Matthew Herper

BioTech

Matt & Adam’s Take: Amylyx did the right thing by withdrawing its ALS drug. That’s rare and worthy of praise

On Thursday morning, Amylyx Pharmaceuticals announced that it would withdraw its ALS drug, Relyvrio, after a large clinical trial showed that the medicine, approved by

Adam Feuerstein and Matthew Herper April 4, 2024

BioTech

Vivek Ramaswamy wants to ‘gut’ the FDA. His claims don’t hold up to scrutiny

STAT readers know Vivek Ramaswamy from his time as the founder of the biotech conglomerate Roivant — and for his role in some of its

Adam Feuerstein and Matthew Herper July 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Adam Feuerstein and Matthew Herper

Matt & Adam’s Take: Amylyx did the right thing by withdrawing its ALS drug. That’s rare and worthy of praise

Vivek Ramaswamy wants to ‘gut’ the FDA. His claims don’t hold up to scrutiny

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe